Screening examination of the liver focusing on the occurrence of adenoma in women using hormonal contraception

This study examines the connection between the application of hormonal contraception and the development of liver adenomas. The question was posed whether focal or other liver disorders could be detected by screening women at risk who have used contraceptives for a long time. 160 subjects were selected from 1500 women under regular control who had used contraceptives for over 4 years and/or were 35 years old and the contraceptive contained more than 0.05 mg mestranol per pill. A total of 105 volunteers were studied using a questionnaire about risk factors liver test and sonographic and laboratory findings were hospitalized. 73 (69.5%) women had been using Biogest containing 0.08 mg mestranol per pill for 4 years 70 (66.7%) had used a hormonal contraceptive for over 4 years and 39 (27.1%) women were over 35. Only 19 women (18%) were obese but 40 (38%) smoked and 81 (77.1%) had 2 children. NO focal liver disorder was demonstrated by sonography. Cholecystolithiasis was the most common finding and in 15 cases it was clinically symptomless. There were 34 (32.4%) pathological or abnormal cases. IN addition there were 8 cases of steatosis 6 cases of hepatomegaly 3 cases of nephrolithiasis and 2 cases of increased ALT and bilirubin values. The average age of patients was 36.4 years the average duration of use of preparations 6.5 years and the majority of them had type A blood. Although no connection was established between hormonal contraception and focal liver disorders sonography still proved to be a useful method for screening asymptomatic cases.